Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
Mobia Medical published two-year follow-up data from the VNS-REHAB trial in Neurology, demonstrating that motor function improvements from Vivistim Paired VNS Therapy are sustained for at least two years post-treatment. Results from 49 participants showed a 76% responder rate with average gains on the Fugl-Meyer Assessment and Wolf Motor Function Test exceeding minimum clinically important differences.
Key figures
- Responder rate
- 76%
- Follow up years
- 2
- Participants 2yr
- 49
- Participants 3yr
- 16
- Wmft improvement
- 0.63
- Fma ue improvement
- 7.5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.